UNCLASSIFIED

AD NUMBER

ADB265796

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Nov 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.

AUTHORITY

USAMRMC ltr, dtd 10 Jun 2003

THIS PAGE IS UNCLASSIFIED

AD

Award Number: DAMD17-99-1-9064

TITLE: Heparan sulfate proteoglycans as therapeutic agents for breast cancer

PRINCIPAL INVESTIGATOR: Carla Y. Pumphrey, Ph.D. Ralph D. Sanderson, Ph.D.

CONTRACTING ORGANIZATION: University of Arkansas for Medical Sciences Little Rock, Arkansas 72205

REPORT DATE: November 2000

TYPE OF REPORT: Annual summary training report

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010507 014

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER DOES NOT GOVERNMENT PROCUREMENT IN ANY WAY THAN FACT U.S. GOVERNMENT. THE THAT THE OBLIGATE THE DRAWINGS, GOVERNMENT FORMULATED OR SUPPLIED THE SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9064 Organization: University of Arkansas for Medical Sciences Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

<u>Carale B. Clustin</u> <u>4-23-01</u>

ACTION CONTRACT OF THE ADDRESS OF T	REPORT DOCUMENTATION PAGE			1	Form Approved
The device of	Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing in			Structions, searching exis	ABINO, U74-U100 sting data sources, gathering and maintaining
1. AGENCY USE ONLY (Lever blank) 2. REPORT OFF 3. REPORT TYPE AND DATE SCONGER (MOV 97-3) (ORLOW) 4. TITLE AND SUBTITLE 3. REPORT TYPE AND DATES SCONGER (MOV 97-3) (ORLOW) 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS Report an sulfate proteoglycans as therapeutic 5. FUNDING NUMBERS (agents for breast cancer 5. FUNDING NUMBERS 6. AUTHOR(S) Carla Y. Pumphrey, Ph.D. Make and the state of the state	he data nea "'ut and completing and reviewing this co reducing this burden to Washington Headquarters Sen Nanous and Burdet Bacquist Participation Provi	election of information. Send comments regardi- vices. Directorate for Information Operations and out (0704-0188). Washington, DC 20503.	ng this burden estimate or any othe d Reports, 1215 Jefferson Davis H	her aspect of this collecti fighway, Suite 1204, Art	ion of information, including suggestions for ington, VA 22202-4302, and to the Office of
4. TITLE AND SUBTITLE 5. FUNDING NUMBERS 4. TITLE AND SUBTITLE Beparan sulfate proteoglycans as therapeutic agents for breast cancer 6. AUTHOR(S) Carla Y. Pumphrey, Ph.D. Kabb D Sandenson, Ph.D. 7. PERFORMING ORGANIZATION NAME(SI AND ADDRESS(ES) 8. PERFORMING ORGANIZATION NAME(SI AND ADDRESS(ES) University of Arkansas for Medical Sciences 8. PERFORMING ORGANIZATION RAME(SI AND ADDRESS(ES) University of Arkansas 72205 Bumphreycarlay@exchange.uams.edu 9. SPONSORING / MONITORING AGENCY NAME(SI AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(SI AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command AGENCY REPORT NUMEER 11. SUPPLEMENTARY NOTES 10. SPONSORING / MONITORING AGENCY NAME(SI AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION CE 12a. DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION CE 13. ASSTRACT (Maximum 200 Words) 12b. DISTRIBUTION CE 14. SUBJECT (Maximum 200 Words) 12b. DISTRIBUTION CE 15 to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in The first task is to develop brast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sizevels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ecretoin of syndecan-1. wi	1. AGENCY USE ONLY (Leave blank)	2. REPORT, DATE November 2000	3. REPORT TYPE AND Annual summa	DATES COVERF	
Heparan sulfate proteoglycans as therapeutic agents for breast cancer 6. AUTHOR(S) Carla Y. Pumphrey, Ph.D. Rajh D. Smetron, Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Arkansas for Medical Sciences E.Mail: Dumphrey.carlay@exchange.uams.edu S. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command For Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABULITY STATEMENT	4. TITLE AND SUBTITLE			5. FUNDING N	UMBERS
agents for breast cancer 6. AUTHOR(S) Carla Y. Pumphrey, Ph.D. Ralph D. Sanderson, Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESSIES) University of Arkansas for Medical Sciences Little Rock, Arkanss 72205 E-Mail: pumphreycarlay@exchange.uams.edu 3. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESSIES) LUCS. Array Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in 1 The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expression was eval on solar therapy in vitro and in 1 The first task is to d	Heparan sulf	fate proteoglycans as	therapeutic		
Carla Y. Pumphrey, Ph.D. Ralph D. Sanderson, Ph.D. // PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Arkansas for Medical Sciences Little Rock, Arkansas 72205 // Pumphreycarlay@exchange.uams.edu // Seconsormand Addition admost and Nateriel Command // Seconsormand Addition admost and Nateriel Command // Seconsormand Addition admost and Nateriel Command // Seconsormand Addition admost and Seconsormand // Seconsormand Addition admost and Seconsormal Addition // Seconsormand Addition admost and Seconsormand // Seconsormand Addition admost and Seconsormand // Seconsormand Addition // Seconsormand Addition // Seconsormand Addition // Seconsormand // Seconsormadd // Seconsormadd // Secon	agents for h	preast cancer	-		
Carla Y. Pumphrey, Ph.D. Ralph D. Sanderson, Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Arkansas for Nedical Sciences Little Rock, Arkansas 72205 pumphreycarlay@exchange.uams.edu 5. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DIS	6. AUTHOR(S)				
Carla Y. Pumphrey, Ph.D. Raiph D. Sanderson, Ph.D. 7. PERFORMING ORGANIZATION NAMESI AND ADDRESS(ES) University of Arkansas for Medical Sciences Little Rock, Arkansas 72205 E-Mail: pumphreycarlay@exchange.uams.edu 9. SPONSORING / MONITORING AGENCY NAMESI AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nor 60). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, SM Sci Struck, For Detrick, Manymad 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Army Medical Research and Materiel Command, SM Sci Store, For Detrick, Manymad 21702-9012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in - The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and si levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, trunc					
Raph D. Sanderson, Ph.D. 2. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 3. University of Arkansas for Medical Sciences 4. Little Rock, Arkansas 72205 9. pumphreycarlay@exchange.uams.edu 10. 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. U.S. Army Medical Research and Materiel Command AGENCY REPORT NUMBER For Detrick, Maryland 21702-5012 10. 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT. Distribution authorized to U.S. Government agencies only (proprietary information, Nov 60). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command. 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT. Distribution authorized to U.S. Army Medical Research and Materiel Command. 12b. OISTRIBUTION STATEMENT. Distribution authorized to U.S. Army Medical Research and Materiel Command. 12b. DISTRIBUTION CC 13. ABSTRACT (Maximum 200 Words/ 12b. DISTRIBUTION TATEMENT. Distribution authorized to U.S. Army Medical Research and Materiel Command. 12b. DISTRIBUTION CC 13. ABSTRACT (Maximum 200 Words/ 12b. DISTRIBUTION CC 12b. DISTRIBUTION CC 13. ABSTRACT (Maximum 200 Words/ 12b. DISTRIBUTION CC 12b. DISTRIBUTION CC 13. DISTRIBUTION TATEM	Carla Y. Pun	nphrey, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION University of Arkansas for Medical Sciences 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 12a. DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIBUTION / AVAILABULTY STATEMENT 12b. DISTRIBUTION / AVAILABULTY STATEMENT DISTRIB	Ralph D. Sanderson,	, Ph.D.	·		·
University of Arkansas for Medical Sciences Little Rock, Arkansas 72205 Pumphreycarlay@exchange.uams.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND AODRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABULITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, Sol Sout State, For Detrick, Maryland 21702-012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate protoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> 1 The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1 will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-1 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, w	7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			8. PERFORMIN	G ORGANIZATION MBER
E-Mail: Little Rock, Arkansas 72205 pumphreycarlay@exchange.uams.edu . 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command AGENCY REPORT NUMBER Fort Detrick, Maryland 21702-5012 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Soci Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> 1 The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sit levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th engineering enders. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable	University of Arkansas for Medical Sciences				
pumphreycarlay@exchange.uams.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in 1 The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of umorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene threapy. MDA-1 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1	Little Rock, Arkansas 72205				
pumphreycarlay@exchange.uams.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in 1 The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval 1 evels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects or tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-31 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur di dot grow. In addition, we were unable to confirm that the syndecan-		_			
3: SPONSOUND Y MONITORING AGENCT NUMERST AND AUDRESS(S) 10: SPONSOUND Y MONITORING U.S. Army Medical Research and Materiel Command AGENCY REPORT NUMBER Fort Detrick, Maryland 21702-5012 11: SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) 13: ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in 1 The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sit levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the in vivo studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	pumphreycar	lay@exchange.uams.edu	· · · · · · · · · · · · · · · · · · ·	10.5000500	
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT <i>IMaximum 200 Words!</i> Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> is 12evels of syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA- 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES	9. SPONSORING / MONITORING AGE	INCY NAME(S) AND ADDRESS(ES	1	AGENCY F	EPORT NUMBER
11. SUPPLEMENTARY NOTES 12.a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. Will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects or tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a echnical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES	U.S. Army Medical Research and Materiel Command				
11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, S04 Scott Street, For Detrick, Maryland 21702-5012. 12b. DISTRIBUTION CC 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES 10	Torr Detrick, Maryland 21702-001				
11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in 'The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn l gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 12b. DISTRIBUTION CC 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in the first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing the length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control ture did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	11. SUPPLEMENTARY NOTES		u	<u> </u>	
12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in the first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syndecan-1. tevels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of syndecan-1 gene. The results down or reduction in tumor size however, even the untreated control turd did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the in vivo studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CC DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 12b. DISTRIBUTION CC 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> . The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and silevels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES					
Distribution of the request of U.S. Overnment agences only (proprietary information, Nov 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy in vitro and in 'The first task is to develop breast cancer gene therapy and evaluate in vitro. Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sit levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syr 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES	12a. DISTRIBUTION / AVAILABILITY S	STATEMENT			12b. DISTRIBUTION CODE
504 Scott Street, Fort Detrick, Maryland 21702-5012. 13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> . The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the synt gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	Nov 00). Other requests for this document s	shall be referred to U.S. Army Medical I	Research and Materiel Com	mation, mand,	
13. ABSTRACT (Maximum 200 Words) Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> . The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	504 Scott Street, Fort Detrick, Maryland 21	702-5012.			
Heparan sulfate proteoglycans (HSPGs) represent a new class of tumor suppressors. The goal of the propose is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> . The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA- 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS	13. ABSTRACT (Maximum 200 Word		· · · · · · · · · · · · · · · · · · ·		
is to evaluate the cell growth inhibitory affects and apoptotic potential of HSPG gene therapy <i>in vitro</i> and <i>in</i> The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	Heparan sulfate proteoglycans	(HSPGs) represent a new	class of tumor sup	pressors. The	goal of the proposed work
The first task is to develop breast cancer gene therapy and evaluate <i>in vitro</i> . Syndecan-1 expression was eval on several breast cancer cell lines. The results demonstrate that each cell line expresses an abundance and sin levels of syndecan-1. Therefore, DNA encoding a c-myc tag was incorporated into the ectodomain of the syn 1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA- 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	is to evaluate the cell growth is	nhibitory affects and apopt	otic potential of H	SPG gene the	rapy <i>in vitro</i> and <i>in vivo</i> .
I per estit a fer a suburdance and s	The first task is to develop bre	ast cancer gene therapy and	d evaluate <i>in vitro</i> .	Syndecan-1	expression was evaluated
1 gene. In addition, truncated gene cassettes have been constructed to allow for the secretion of syndecan-1. will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA- 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS	on several breast cancer cell III	nes. The results demonstrative DNA encoding a c myc	te that each cell li	ted into the o	an abundance and similar
will next isolate breast cancer cell lines expressing the engineered gene constructs and determine the effects of tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA-231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing the length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control ture did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES 10 10 10 10 10 10 10 10 10 1	1 gene. In addition, truncated	gene cassettes have been c	onstructed to allow	for the secre	tion of syndecan-1 We
tumorigenicity. The second task of the proposal is the <i>in vivo</i> analysis of breast cancer gene therapy. MDA- 231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 15. NUMBER OF PAGES 10	will next isolate breast cancer	cell lines expressing the en	gineered gene con	structs and de	etermine the effects on
231 breast tumors were established in SCID mice and treated by electroporation with a plasmid containing th length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES 10 10 10 10 10 10 10 10 10 1	tumorigenicity. The second ta	sk of the proposal is the in	vivo analysis of br	east cancer g	ene therapy. MDA-MB-
length syndecan-1 gene. The results show no reduction in tumor size however, even the untreated control tur did not grow. In addition, we were unable to confirm that the syndecan-1 gene was over expressed due to a technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES 10	231 breast tumors were establi	shed in SCID mice and tre	ated by electropora	tion with a p	lasmid containing the full
technical error. We have addressed these problems and are proceeding with the <i>in vivo</i> studies. This project represents the first attempt to use HSPG genes for anti-cancer therapy.	length syndecan-1 gene. The r	results show no reduction in	n tumor size howe	ver, even the	untreated control tumors
represents the first attempt to use HSPG genes for anti-cancer therapy. 14. SUBJECT TERMS 15. NUMBER OF PAGES	technical error. We have addr	were unable to confirm that	it the syndecan-1 g	the in vivo s	expressed due to a
14. SUBJECT TERMS	represents the first attempt to i	use HSPG genes for anti-ca	incer therapy.		udies. This project
			FJ		15. NUMBER OF PAGES
	IT, SUBJECI TERMIS				10
heparan sulfate proteoglycans, gene therapy, apoptosis	heparan su	lfate proteoglycans, g	gene therapy, a	poptosis	16. PRICE CODE
17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION OF ABS	17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASS	IFICATION	20. LIMITATION OF ABSTRACT
Unclassified Unclassified Unclassified Unclassified Unclassified	Unclassified	Unclassified	Unclassi	fied	Unlimited
NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-8 Prescribed by ANSI Std. Z39-18	NSN 7540-01-280-5500		.	Sta	ndard Form 298 (Rev. 2-89) cribed by ANSI Std. Z39-18

Table of Contents

•

Cover	
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	9
Reportable Outcomes	9
Conclusions	9
References	n/a
Appendices	n/a

(4). INTRODUCTION

Heparan sulfate proteoglycans (HSPGs) regulate normal and cancer cell behaviors by binding growth factors, and by mediating cell adhesion and invasion. Current data strongly support the idea that HSPGs are a new class of tumor suppressors. Studies demonstrate the anti-tumor growth properties of three HSPGs, specifically syndecan-1, glypican-1, and betaglycan. Treatment with purified syndecan-1 produces strong growth suppression in multiple myeloma cell lines, a poorly differentiated squamous cell carcinoma cell line, human and murine mammary tumor cell lines, but not normal cell lines. In addition, treatment of multiple myeloma cells with purified syndecan-1 induces apoptosis. Many tumors display an alteration in cell surface HSPG expression. When syndecan-1 is lost from the surface of mammary epithelia, the cells lose epithelial morphology, invade collagen gels and show characteristics of neoplastic growth. When transfected with the syndecan-1 gene, transformed mammary epithelial cells regain morphology and lose neoplastic growth characteristics. In vivo experiments demonstrate reduced tumorigenicity of syndecan-1 or glypican-1 expressing multiple myeloma cells and betaglycan expressing breast cancer cells. Therefore, we propose that HSPGs are excellent candidates for gene therapy applications for the treatment and possible eradication of breast cancer. The purpose of the proposed work is to develop HSPG gene therapy and examine HSPGs independently and in combination as mediators of breast cancer cell growth and apoptosis *in vitro* and *in vivo*. This work represents a novel use of HSPGs as anti-cancer therapy.

(5). BODY

Task 1. Develop breast cancer gene therapy and evaluate *in vitro*.

• Engineer epitope tag containing human HSPG gene constructs for cell surface expression or secretion.

Ideally, to determine the effect of expression of a transfected gene, the parental cell lines should not actively produce the gene product. This allows for a direct comparison between the behavior of the parental non-expressing cell line and the behavior of the same cell line that expresses the transfected gene. Syndecan-1 expression has been characterized on the cell surface of several breast cancer cell lines including MCF-7, MDA-MB-231, MDA-MB-435, MDA-MB-436, and Hs578t. The breast cancer cell lines were grown as monlayers in tissue culture flasks, detached by treatment with 1% EDTA only (trypsin cleaves syndecan-1 from the cell surface), stained with the FITC-labeled BB4 monoclonal antibody which is specific for syndecan-1, and analyzed by FACS. Each of these cell lines express significant and in fact abundant levels of syndecan-1 (Figure 1

and data not shown.) The mean fluorescence intensity of BB4-FITC staining on each cell line was compared in duplicate experiments and the results indicate that the cell lines express roughly similar amounts of syndecan-1 (Figure 2). Therefore, for the purpose of distinguishing native syndecan-1 from syndecan-1 expressed from transferred gene cassettes, a c-myc tag was incorporated into the human syndecan-1 gene construct. The c-myc tag was inserted 3' to the DNA sequence encoding the amino-terminal signal sequence and 5' to the glycosaminoglycan attachment sites. Primers for the production of three syndecan-1 gene cassettes including a full length cassette and two truncated constructs have been engineered and used to PCR amplify the appropriate DNA fragments (Figure 3). Expression of the truncated cassettes will generate syndecan-1 that will be secreted instead of found on the cell surface. The three syndecan-1 gene constructs have been cloned in plasmid vectors.

Task 2. In vivo analysis of breast cancer gene therapy.

• Establish tumors in the mammary fat pads of NUDE mice. Treat tumors with therapeutic HSPG delivered by retrovirus or liposomes. Evaluation HSPG gene localization, expression, tumor burden, and induction of apoptosis.

In vivo experiments have begun to test the effect of increased syndecan-1 expression on tumor growth. MDA-MB-231 breast cancer cells were injected into the mammary fat pad of SCID mice and tumors were established. Plasmid DNA only or plasmid DNA containing the full length human syndecan-1 gene cassette was electroporated into tumors two times per week for several weeks. Tumor growth was measured every other day and at the end of the experiment the animals were sacrificed and the tumors excisized and stained for syndecan-1 expression. The results showed no reduction in tumor size however, the tumors were initially very small and did not grow appreciably regardless of treatment. The data from the tumor staining was inconclusive due to technical error. Therefore, we are not sure that syndecan-1 was effectively expressed.

To address these issues, we have amended our protocols. First we have treated the MDA-MB-231 cells in culture with an antibiotic for mycoplasma which should increase tumor growth *in vivo*. In addition, we have switched to the NUDE mouse model to eliminate any possible interference by the immune system. We have found that with these two amendments we can establish and grow tumors. Therefore, this task is moving forward.



This page contains proprietary data

Figure 1. Breast cancer cell lines express abundant syndecan-1 on the cell surface. HBL-100 (A), MCF-7 (B), MDA-MB-435 (C), MDA-MB-436 (D), and MDA-MB-231 (E) breast cancer cell lines were stained with BB4-FITC monoclonal antibody to syndecan-1 or an isotype matched control FITC-labeled antibody. FACS analysis reveals a shift in fluorescence when cells were stained with BB4 (dark line) verses control antibody (lighter line) indicating extensive amounts of cell surface syndecan-1 on each breast cancer cell line.



Figure 2. Breast cancer cell lines express similar amounts of syndecan-1 on the cell surface. Breast cancer cell lines were stained with BB4-FITC and analyzed by FACS in duplicate experiments. The mean fluorescence intensity, which indicates the amount of cell surface syndecan-1 present on each cell line was compared. Error bars reflect standard deviation. Lane 1., HBL-100, lane 2., MCF-7, lane 3., MDA-MB-231, lane 4., MDA-MB-435, and lane 5., MDA-MB-436.







B. Full length syndecan-1 forward primer: 5' cgcggatcctccgggcagcatgaggcg c-myc tag insertion primer: 5'ctgcagctggccctggaacagaaactcatctctgaagaggatctgccgcaaattgtggct Full length syndecan-1 reverse primer: 5'cccaagcttgcgtcaggcatagaattcctc Truncated syndecan-1 reverse primers: 5'cccaagctttcactgatccactggggactg 5'cccaagctttcactgatccactggggactg

Figure 3. Full length and truncated syndecan-1 protein structure and primers for gene construction. Panel A. illustrates the c-Myc tagged full length syndecan-1 and two truncated forms. The full length syndecan-1 is composed of an N-terminal signal sequence (gray box), an ectodomain (open box) containing glycosaminoglycan attachment sites (lines), a transmembrane domain (hatched box), and a cytoplasmic domain (black box). The c-Myc tag (dotted box) was inserted in the ectodomain between the signal sequence and glycosaminoglycan attachment sites. One truncated form of syndecan-1 lacks the transmembrane and cytoplasmic domains while the other lacks these domains along with most of the ectodomain. Panel B. list the primers used to insert the c-myc tag into the syndecan-1 gene and the primers used for the production of full length and truncated syndecan-1 gene cassettes. The syndecan-1 start codon and the c-myc tag DNA sequences are in bold.

(7). 1). KEY RESEARCH ACCOPLISHMENTS

Task 1.

- Syndecan-1 expression profile was determined on several breast cancer cell lines including MCF-7, MDA-MB-231, MDA-MB-435, MDA-MB-436, and Hs578t. Each of these cell lines express abundant amounts of syndecan-1 on the cell surface.
- A c-myc tag has been added 3' to the amino-terminal signal sequence of the syndecan-1 gene construct.
- Two truncated syndecan-1 gene constructs have been produced by PCR amplification and cloned in plasmid vectors.

Task 2.

• Treatment of breast cancer tumors in SCID mice with the full length human syndecan-1 gene was inconclusive.

CONCLUSIONS

The objective of the proposal is to transfer HSPG gene constructs into breast cancer cells lines and tumors growing in mice to test the ability of these tumor suppressor genes to slow growth and possibly eradicate tumors. Several different syndecan-1 gene cassettes have been produced during this year and the full length syndecan-1 gene has been electroporated into established breast cancer tumors in SCID mice. While the results of the *in vivo* study were inconclusive, we are confident that we have worked out the technical difficulties and will address this important question. This work represents the first attempt to use HSPG genes for the purpose of anti-cancer therapy.



DEPARTMENT OF THE ARMY US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 504 SCOTT STREET FORT DETRICK, MD 21702-5012

MCMR-RMI-S (70-1y)

10 Jun 03

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det,amedd.army.mil.

FOR THE COMMANDER:

PHYLIS M. VRINEHART Deputy Chief of Staff for Information Management

Encl

100220940	
ADB2/0849	
ADB263653	
ADB282255	
ADB262232	
ADB277418	
ADB285664	
ADB281628	
ADB284965	
ADB265796	
ADB282152	
ADB285670	
ADB257200	
ADB266081	
ADB285703	
ADB285699	
ADB285481	
ADB285668	
ADB283633	

,

7